BiomX Inc. (PHGE-UN)
USD 0.9
(-5.26%)
USD 0.9
(-5.26%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 15.09 Million USD | -22.04% |
| 2022 | 19.35 Million USD | -3.29% |
| 2021 | 20.01 Million USD | 239.54% |
| 2020 | 5.89 Million USD | 378.88% |
| 2019 | 1.23 Million USD | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 40 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 9.89 Million USD | -2.25% |
| 2024 Q1 | 10.12 Million USD | -32.92% |
| 2023 FY | 15.09 Million USD | -22.04% |
| 2023 Q3 | 16.2 Million USD | -7.91% |
| 2023 Q1 | 18.77 Million USD | -3.0% |
| 2023 Q2 | 17.6 Million USD | -6.27% |
| 2023 Q4 | 15.09 Million USD | -6.89% |
| 2022 Q4 | 19.35 Million USD | 0.01% |
| 2022 FY | 19.35 Million USD | -3.29% |
| 2022 Q3 | 19.35 Million USD | -0.26% |
| 2022 Q2 | 19.4 Million USD | -2.45% |
| 2022 Q1 | 19.89 Million USD | -0.6% |
| 2021 Q1 | 5.5 Million USD | -6.68% |
| 2021 Q4 | 20.01 Million USD | 1.34% |
| 2021 Q3 | 19.75 Million USD | 248.36% |
| 2021 Q2 | 5.67 Million USD | 3.07% |
| 2021 FY | 20.01 Million USD | 239.54% |
| 2020 Q3 | 4.49 Million USD | 335.11% |
| 2020 Q1 | 1.1 Million USD | 0.0% |
| 2020 Q4 | 5.89 Million USD | 31.03% |
| 2020 FY | 5.89 Million USD | 378.88% |
| 2020 Q2 | 1.03 Million USD | -6.09% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | -100.0% |
| 2019 Q2 | 500 Thousand USD | 0.0% |
| 2019 Q1 | 500 Thousand USD | 0.0% |
| 2019 FY | 1.23 Million USD | 0.0% |
| 2018 Q3 | 73.5 Thousand USD | 0.0% |
| 2018 FY | - USD | -100.0% |
| 2018 Q4 | 500 Thousand USD | 580.27% |
| 2017 FY | 40 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | -2948.889% |
| Ampio Pharmaceuticals, Inc. | 274 Thousand USD | -5408.029% |
| Armata Pharmaceuticals, Inc. | 120.37 Million USD | 87.462% |
| Actinium Pharmaceuticals, Inc. | 2.11 Million USD | -614.245% |
| Azitra, Inc. | 885.94 Thousand USD | -1603.488% |
| Can-Fite BioPharma Ltd. | 39.99 Thousand USD | -37630.943% |
| Chromocell Therapeutics Corporation | 1.26 Million USD | -1089.578% |
| Calidi Biotherapeutics, Inc. | 7.23 Million USD | -108.568% |
| CEL-SCI Corporation | 13.57 Million USD | -11.202% |
| iBio, Inc. | 4.46 Million USD | -238.386% |
| Lineage Cell Therapeutics, Inc. | 2.95 Million USD | -411.247% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 3.55 Million USD | -324.409% |
| Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | -519.972% |
| NovaBay Pharmaceuticals, Inc. | 2.74 Million USD | -450.803% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 312.7 Thousand USD | -4726.305% |
| BiomX Inc. | 15.09 Million USD | 0.0% |
| Protalix BioTherapeutics, Inc. | 26.28 Million USD | 42.574% |
| Palatin Technologies, Inc. | 590.33 Thousand USD | -2456.502% |
| Scorpius Holdings, Inc. | 14.04 Million USD | -7.477% |